Home » Stocks » Celyad

Celyad S.A. (CYAD)

Stock Price: $10.35 USD 0.20 (1.97%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 144.30M
Revenue (ttm) 6,742
Net Income (ttm) -32.17M
Shares Out 13.94M
EPS (ttm) -7.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $10.35
Previous Close $10.15
Change ($) 0.20
Change (%) 1.97%
Day's Open 10.26
Day's Range 10.20 - 10.35
Day's Volume 1,016
52-Week Range 4.10 - 14.98

More Stats

Market Cap 144.30M
Enterprise Value 105.01M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 13.94M
Float 11.43M
EPS (basic) n/a
EPS (diluted) -7.01
FCF / Share -2.59
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 8,706
Short Ratio 0.23
Short % of Float n/a
Beta 1.47
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 21,404.92
PB Ratio 2.52
Revenue 6,742
Operating Income -38.49M
Net Income -32.17M
Free Cash Flow -32.39M
Net Cash 39.30M
Net Cash / Share 2.82
Gross Margin 100.00%
Operating Margin -571,000.00%
Profit Margin -477,200.00%
FCF Margin -480,400.00%
ROA -20.02%
ROE -56.58%
ROIC -346.50%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 6
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$24.69*
(138.55% upside)
Low
20.0
Current: $10.35
High
42.2
Target: 24.69
*Average 12-month USD price target from 6 stock analysts.

Financial Performance

Financial numbers in millions EUR.

Financial Overview

Year2019201820172016201520142013
Revenue0.013.123.5410.01-0.15-
Revenue Growth-99.81%-12.01%-64.64%333633.33%-97.95%--
Gross Profit0.013.123.038.47-0.03-
Operating Income-34.26-30.85-55.47-28.95-29.67-16.44-3.92
Net Income-28.63-37.43-56.40-23.61-29.11-16.45-0.01
Shares Outstanding12.5211.149.639.318.486.754.10
Earnings Per Share-2.29-3.36-5.86-2.53-3.43-2.44-353.00
Operating Cash Flow-28.20-27.25-44.44-24.69-27.28-17.41-10.64
Capital Expenditures-0.62-1.69-0.86-1.70-0.84-0.64-0.53
Free Cash Flow-28.82-28.94-45.30-26.40-28.12-18.05-11.17
Cash & Equivalents39.3440.5423.2548.3610027.7019.06
Total Debt4.361.651.441.480.680.410.11
Net Cash / Debt34.9838.9021.8146.8899.5027.2918.95
Assets89.8494.3077.6313916043.9832.39
Liabilities44.2238.7130.0947.9248.0517.2915.49
Book Value45.6255.5947.5490.8911126.6816.90
Numbers in millions EUR, except per-share numbers.

Company Profile

Company Details

Full Name Celyad S.A.
Country Belgium
Employees 105
CEO Filippo Joseph Petti

Stock Information

Ticker Symbol CYAD
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CYAD

Description

Celyad Oncology, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies for the treatment of cancer. The company's lead drug product candidates include CYAD-01 and CYAD-02 autologous cell therapies, which are in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. It is also developing CYAD-101, an allogeneic cell therapy that is in Phase I clinical trial for the treatment of metastatic colorectal cancer; and CYAD-103, an allogeneic CAR-T product candidate that is in preclinical development for the treatment of solid tumors. The company's other preclinical candidates include CYAD-211, a CAR-T candidate targeting B-cell maturation antigen for the treatment of multiple myeloma; CYAD-221, a CAR-T candidate targeting CD19 for the treatment of B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting NKG2D and an undisclosed membrane protein. Celyad Oncology has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad Oncology was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.